Company: RGNT
Filing Date: 2025-02-12
Form Type: DRS/A
Source: 0001213900-25-012299
Chunk: 123

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-02-12
Form: DRS/A
Chunk 123
---
 actual patents. The final product uses a ready–for–use
formulation technology and the process of manufacture of the final product avoids the use of acetone, which may become forbidden
under advanced guidelines for products introduced into the body. Therefore, we believe that upon approval in different territories,
additional patents could provide the Company with sufficient protection from completion even after the expiration dates of the basic
patent estate.

GelrinC

GelrinC utilizes a conjugate
of denatured fibrinogen and polyethylene glycol and the intended clinical use of this product is to treat focal cartilage injuries. These
specific conjugate molecules are disclosed and claimed in the earliest patent family of the Company derived from WO 2005/061018, which
are nominally due to expire in December 2025. In various countries, patent term extension or supplementary protection certificates are
available upon receipt of marketing approval to prolong the period of exclusivity of a new medical product. The earliest patent family
of the Company derived from WO 2005/061018 includes patents Nos. US 7,842,667, US 8,007,774, US 8,858,925, US 9,120,872, US 9,474,830,
US 9,700,600 and EP 1870115, which are detailed in the table below.

While the first family
of patents form the “basic patent estate” covering the current products of the Company, diligent efforts have been made
by the Company to cover improvements and alternatives. Our “basic patent estate” has expiration date in December 2025.
Although the patents included in this “basic patent estate” are close to expiring, such patents only cover certain
components in the Company’s products. Our additional subsequently granted patents provide supplementary protection, as well as
the latest pending patent applications which cover subsequent improvements in the Company’s products and processes.
Furthermore, regulatory approval, when obtained, will yield certain types of non-patent exclusivities that can maintain the
Company’s advantage even after expiration of the earlier “basic patent estate”.

<div align='center'>75</div>

We also have additional subsequent
patents that we believe could prevent competitors from entering the market when patents directed to the specific conjugate molecules expire.
The additional patents are directed to manufacturing processes, formulations and other important technologies and serve to support and
extend patent protection beyond the earliest patents. While it is a fact that the earliest patent families are due